—

TAKEDA PHARMACEUTICAL CO LTD

Q3 2025 13F Holdings

  • Location
    tokyo, M0
  • Num holdings

    8

  • Value ($000)

    $16,369

  • Date Filed
    11/13/2025
  • Form type
    13F-HR
  • CIK
    0001395064
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q3 2025 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
O
OVID

Ovid Therapeutics, Inc.

COM
690469101
$9.79M
60 %

7,531,996

E
EQ

Equillium, Inc.

COM
29446K106
$2.61M
16 %

1,824,977

X
XLO

Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics)

COM
98422T100
$1.24M
8 %

1,475,121

S
STTK

Shattuck Labs, Inc.

COM
82024L103
$1.23M
8 %

515,619

L
LYEL

Lyell Immunopharma, Inc.

COM
55083R104
$891.37K
5 %

54,887

A
AMWL

American Well Corporation

COM
03044L204
$478.06K
3 %

77,733

R
RANI

Rani Therapeutics Holdings, Inc.

COM
753018100
$101.55K
1 %

203,190

F
FLB

Standard Biotools, Inc.

COM
34385P108
$21.47K
0 %

16,515

Rows Per Page
10
  • 5
  • 10
  • 20
  • 30
  • 50
  • 100
1 - 8 of 8